Funding for this research was provided by:
Received: 19 February 2021
Accepted: 6 June 2021
First Online: 1 July 2021
: Participants completed an informed consent form, approved by the Independent Ethics Committee and sponsor before study initiation. This study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with International Council for Harmonization/Good Clinical Practice, applicable regulatory requirements. EC CHU Sart Tilman, 2019/57, B-4000, Belgium; Universitair Medisch Centrum Groningen, 2018/466, 9700 RB.
: Not applicable.
: MvdB reports research grants paid to his institution from AstraZeneca, Chiesi, GlaxoSmithKline, and TEVA Pharma. JDB is the Chief Executive Officer and founder of FLUIDDA and holds shares in the company. CVH is an employee of FLUIDDA. WDB has no real or perceived conflicts of interest that relate to this manuscript. His department has received grants from AstraZeneca, Chiesi, and GlaxoSmithKline. RT, MJ, PD, and MA are employees of AstraZeneca and hold stock and/or stock options in the company.